• Dr. Roger Estrada Tejedor

Dr. Roger Estrada Tejedor
Pharmaceutical Chemistry Group
IQS School of Engineeering
Universitat Ramon Llull
Via Augusta 390, E-08017 Barcelona, Spain
Tel.:+34 932 672 000
Fax: +34 939 056 266

 

email: 
roger.estrada @iqs.url.edu

Assistant Professor (2013), Lecturer (AQU,2015).

Master's degree in Applied Statistics (2013, UNED). PhD at Ramon Llull University (URL, 2011). Chemical Engineer degree at IQS (IQS, 2006). Degree in Chemistry at Institut Químic de Sarrià (IQS), Ramon Llull University (URL, 2004).

 

SubjectS

Mathematics (Chemistry and Chemical Engineering). Applied mathematics (Biotechnology). Molecular Design (Master in Pharmaceutical Chemistry). Physics (Degree in Pharmacy).
 
 

Research Lines

  • Computer-aided drug design.
  • Implementation of new algorithms based on artificial intelligence and its application in medicinal chemistry.
 

Representative publications

L. Sbicca, A. López González,A. Gresika, A. Di Giorgio, J. Teixido Closa, R. Estrada Tejedor, M. Andréola, S. Azoulay, N. Patino, Exploring the impact of the side-chain length on peptide/RNA binding events, Physical Chemistry Chemical Physics, 2017, 19, 18452 - 18460

A. L. González, P. Konieczny, B. Llamusi, E. Delgado-Pinar, J.I. Borrell, J. Teixidó, E. García-España, M. Pérez-Alonso, R. Estrada-Tejedor, R. Artero, In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models, PLOS one 2017, DOI: 10.1371/journal.pone.0178931

I.Chaib; N.Karachaliou; S.Pilotto; J.Codony Servat; X.Cai; X.Li; A.Drozdowskyj; C.Codony Servat; J.Yang; C.Hu; A.Felipe Cardona; G.Lopez Vivanco; A.Vergnenegre; J.M.Sanchez; M.Provencio; F. de Marinis; A.Passaro; E.Carcereny; N.Reguart; C.Garcia Campelo; C.Teixido; I.Sperduti; S.Rodriguez; C.Lazzari; A.Verlicchi; I. de Aguirre; C.Queralt; J.Wei; R.Estrada; R.Puig de la Bellacasa; J.L.Ramirez; K.Jacobsen; H.J. Ditzel; M.Santarpia; S.Viteri; M.A.Molina; C.Zhou; P.Cao; P.C. Ma; T.G. Bivona; R.Rosell, Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC, Journal of the National Cancer Institute, 2017, 109(9), doi: 10.1093/jnci/djx014.

E.Bou-Petit, E.Picas, C.Puigjaner, M.Font-Bardia, N.Ferrer, J.Sempere, R.Puig de la Bellacasa, X.Batllori, J.Teixidó, R.Estrada-Tejedor, S.Ramon y Cajal J.I.Borrell, An Unequivocal Synthesis of 2-Aryl Substituted 3-Amino-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-b]pyridin-6-ones, Chemistry Select 2017, 2, 3668-3672. DOI: 10.1002/slct.201700732

A.Balmori, M.Chioua, R.Puig de la Bellacasa, R.Estrada-Tejedor, L.Ismaili, J.Marco-Contelles, J.I.Borrell, 5-Amino-6,7,8,9-Tetrahydrobenzo[b][1,8] Naphthyridin-2 (1H)-One: The first Example of a new Family of HuperTacrines for Alzheimer’s Disease Therapy, Chemistry Select 2017, 2, 2605-2610. DOI:10.1002/slct.201700289

M. Camarasa; R. Puig de la Bellacasa; À.L. González; R. Ondoño; R. Estrada-Tejedor; S. Franco; R. Badia; J. Esté; M.A. Martínez; J. Teixidó; B. Clotet; J.I. Borrell, Design, synthesis and biological evaluation of pyrido[2,3-d]pyrimidin-7-(8H)-ones as HCV inhibitors, 2016, European Journal of Medicinal Chemistry, 115:463-483.

À. L. González; J. Teixidó; J.I. Borrell; R. Estrada-Tejedor, On the applicability of elastic network models for the study of RNA CUG trinucleotide repeat overexpansion, 2016, PLoS ONE, http://dx.doi.org/10.1371/journal.pone.0152049.

M. Camarasa; R. Puig de la Bellacasa; À.L. González; R. Ondoño; R. Estrada-Tejedor; S. Franco; R. Badia; J. Esté; M.A. Martínez; J. Teixidó; B. Clotet; J.I. Borrell, Design, synthesis and biological evaluation of pyrido[2,3-d]pyrimidin-7-(8H)-ones as HCV inhibitors, 2016, European Journal of Medicinal Chemistry, 115:463-483

Pascalea, L.; López-González, A.; Di Giorgioa, A.; Gaysinskia, M.; Teixido-Closa, J.; Estrada-Tejedor, R.; Stéphane Azoulay; Nadia Patino, Deciphering structure-activity relationships in a series of Tat/TAR inhibitors, 2015, Journal of Biomolecular Structure & Dynamics

 

Research group